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Stroke risk estimation across nine European countries
in the MORGAM project
Anders Borglykke,1 Anne H Andreasen,1 Kari Kuulasmaa,2 Susana Sans,3
Pierre Ducimetie`re,4 Diego Vanuzzo,5 Marco M Ferrario,6 Luigi Palmieri,7
Juha Karvanen,2 Hugh Tunstall-Pedoe,8 Torben Jørgensen,1 on behalf of the
MORGAM Project
ABSTRACT
Background Previous tools for stroke risk assessment
have either been developed for specific populations or
lack data on non-fatal events or uniform data collection.
The purpose of this study was to develop a stepwise
model for the estimation of 10 year risk of stroke in nine
different countries across Europe.
Methods Using data from the MOnica Risk, Genetics,
Archiving and Monograph (MORGAM) Project,
sex-specific models estimating 10 year risk of stroke were
developed using a Cox regression model stratified by
country and including modelling of competing risks.
Models were developed in a stepwise manner first using
only data from questionnaires, and then adding data from
physical examinations and finally data from blood samples.
Results During 1 176 296 years of observation, 2928
incident fatal and non-fatal events of stroke were
registered. The developed model showed good
calibration and accuracy of prediction. The discrimination
of the model varied between sex and country but
increased with increasing number of variables used (area
under the receiver operating characteristic curve
between 0.77 and 0.79 in men and between 0.75 and
0.80 in women).
Conclusion The present study shows that using a large
multicountry cohort from nine European countries it is
possible to develop a stepwise risk estimation model for
10 year risk of stroke tailored to different availability of
risk factors and still obtain valid measures of risk even in
the simplest form of the model, with increasing
performance of the model following increasing
complexity. The methods chosen which separate this
model from previous models (competing risk and
stepwise approach) should be considered for future risk
estimation models.
INTRODUCTION
During the last two decades several risk appraisal
tools have been developed for prevention of
cardiovascular disease (CVD). Most of these were
developed for coronary heart disease (CHD) or the
combined end point CVD, but few have been
developed for stroke only. The Framingham Heart
Study was the ﬁrst to develop a risk estimation tool
for stroke,1 a model which has since been used in
several guidelines for CVD prevention.
Other stroke risk estimation tools have subse-
quently been developed,2e6 but these models have
been either developed for fatal non-CHD events
only2 or limited to one population.3e6
It has become evident that risk models developed
using data from Framingham have poor predictive
or discriminative ability in other populations.7e9
There is need for risk estimation models that are
sensitive to the differences in absolute risk between
countries. The development of such models
requires a multicentre study across several popula-
tions with a uniform standardised data collection,
as done in the MONICA populations.10 11
In order to be able to tailor models to clinical
settings of diverse resources it could be useful to
develop risk estimation models of increasing
complexity using a stepwise approach. In this way
it is possible to estimate risk based solely on data
from questions, then based on questions and
physical examinations and ﬁnally including data
from blood samples. This approach has, to our
knowledge, never been used before.
The purpose of this study was ﬁrst to develop
a risk model for the estimation of 10 year risk of
fatal and non-fatal stroke in a stepwise approach, in
nine different countries across Europe, and secondly
to estimate the predictive and discriminative ability
of the model in each of the steps and for each of the
countries included.
METHODS
The present study used baseline and follow-up data
on fatal and non-fatal stroke from 16 centres in
nine different European countries from the MOnica
Risk, Genetics, Archiving and Monograph
(MORGAM) collaboration.12 The cohorts included
in the MORGAM study were either examined as
part of the WHO MONICA Project or MONICA
procedures were used at baseline. The three French
PRIME cohorts only included men (table 1). Details
of the cohorts have been described elsewhere.13
Data collection on risk factors at baseline and
cardiovascular end points during the follow-up
were harmonised according to the MONICA and
MORGAMmanuals, respectively.14 15 Diabetes, use
of antihypertensive drugs and daily smoking at
baseline were self-reported. The data from the
baseline physical examinations included body mass
index (BMI), calculated as weight (kg) divided by
the square of the height (m2), and blood pressure,
which was measured twice in the right arm in
a sitting position after 5 min of resting using
a standard mercury or the random-zero mercury
sphygmomanometer,11 except in the French PRIME
cohorts where blood pressure was measured once
using an automated device. In the present study,
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the mean of the two measurements has been used. Total serum
cholesterol and high-desity lipoprotein (HDL) cholesterol were
measured from blood samples.11
Each member of the different MORGAM cohorts was
followed-up for fatal and non-fatal stroke and death from any
cause. Fatal stroke cases were identiﬁed by national or regional
health information systems. Non-fatal strokes were identiﬁed by
a linkage to a speciﬁc population-based stroke register, the
hospital discharge registers or by contacting the cohort
members. Most centres validated the end point events using the
original WHO MONICA diagnostic criteria based on clinical
presentation rather than imaging technique.16 There was an
upper age limit of follow-up for non-fatal stroke in Poland
(65 years), Lithuania (65 years), Russia (75 years) and Sweden
(75 years). These age limits were applied for all follow-up in
these cohorts in this analysis. Details of the baseline and follow-
up procedures used in each cohort, and the quality of the data
have been published elsewhere.17
Statistics
Subjects with documented or self-reported history of myocardial
infarction or stroke at baseline or missing information on one or
several of the included variables were excluded. All included
subjects were used when developing the model, but only those
cohorts with a minimum follow-up of 10 years were used in
validating the model.
All analyses were conducted separately for men and women.
Risk estimation models for 10 year risk of stroke were developed
using a Cox regression model with age as underlying time scale
and a similar Cox regression model for the competing risk of
dying without preceding stroke events. The two developed
models were then combined to give a model for the absolute
risk.18 In this way it is possible to estimate the risk of an event
given that you do not die before the event. The Cox regression
models were stratiﬁed by countrydthat is, the baseline hazard
varies between countries but the effects of the covariates are the
same. Possible interaction terms between country and the
covariates were included one by one to test whether the effect of
the covariate depended on country. Signiﬁcant interactions were
observed in women for smoking. Continuous variables were
modelled using quadratic effects or restricted cubic splines with
knots at 5, 35, 65 and 95% when deviations from linearity were
observed.
Explanatory variables were added to the model in a stepwise
approach simulating the clinical setting, starting with data
obtainable through questions: diabetes (dichotomised (yes/no)),
treatment for high blood pressure (dichotomised (yes/no)) and
smoking (dichotomised (yes/no)); followed by data from
Table 1 Characteristics of the MORGAM populations included in the analyses
No. of all strokes,
fatal and non-fatal
Country Population
Type of cohorts*
(no. of cohorts)
Age range
at baseline
Survey
period
Years of
follow-up
No. of
subjectsy
Total years of
observation _ \ Total
Denmark DEN-GLO
Glostrup
MONICA centre (3) 30, 40, 50, 60 1982e1992 9e19 6483/4978 96232 162 127 289
Finland FIN-EAS
Eastern Finland
and Oulu
MONICA centre and
MONICA procedures (4)
25e64, 25e74z 1982e1997 11e26 16347/12055 270549 464 385 849
FIN-WES
Turku-Loimaa
and Helsinki
MONICA centre and
MONICA procedures (4)
25e64, 25e74 1982e1997 11e26 10257/7204 161514 241 182 423
Sweden SWE-NSW
Northern Sweden
MONICA centre (3) 24e65, 24e74 1986e1994 5e14 4804/1525 43883 50 42 92
Poland POL-WAR
Warsaw
MONICA centre (3) 34e65 1983e1993 2e11 4691/2174 27473 25 11 36
Lithuania LTU-KAU
Kaunas
MONICA centre (3) 33e65 1983e1993 5e11 3908/2781 35506 44 32 76
Russia RUS-NOV
Novosibirsk
MONICA centre and
MONICA procedures (4)
24e65 1983e1995 3e16 5391/2748 37125 25 16 41
France FRA-LIL
Lille
PRIME (MONICA procedures),
men only (1)
49e64 1991e1993 10 2336/2336 22411 38 0 38
FRA-STR
Strasbourg
PRIME (MONICA procedures),
men only (1)
49e60 1991e1993 10 2342/2342 22343 24 0 24
FRA-TOU
Toulouse
PRIME (MONICA procedures),
men only (1)
49e60 1991e1993 10 2423/2423 23176 22 0 22
Italy ITA-BRI
Brianza
MONICA centre (4) 25e66 1986e1994 9e16 4520/3057 55141 39 21 60
ITA-PAM
Pamela
MONICA procedures (1) 25e75 1990e1993 9e12 1888/1888 20207 24 14 38
ITA-ROM
Rome and
area Latina
MONICA centre and
MONICA procedures (4)
19e77 1983e1995 8e19 8561/6643 124970 115 98 213
Scotland UNK-EDI
Edinburgh
MONICA procedures (1) 25e64 1986 19 1233/1233 22472 36 23 59
UNK-GLA
Glasgow
MONICA centre (4) 25e64, 25e75 1986e1995 10e19 4770/4770 62689 130 117 247
UNK-SHH
Nationwide
MONICA procedures (1) 39e59 1984e1987 18e21 8336/8336 150605 248 173 421
All MORGAM cohorts 88290/66493 1176296 1687 1241 2928
*MONICA centre refers to populations included in the original MONICA study. MONICA procedures refer to populations not included but using MONICA procedures.
yNo. of subjects used in the analyses/no. of subjects used for model validation.
zThree cohorts use the age range 25e64, while one cohort use the age range 25e74.
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physical examinations: BMI (modelled as a restricted cubic
spline for men, with quadratic effect for women) and systolic
(SBP) (linear) and diastolic blood pressure (DBP) (linear); ending
with data only obtainable from blood samples: total serum
cholesterol (linear) and HDL cholesterol (modelled as a restricted
cubic spline). Furthermore, the predictive and discriminative
ability of a model consisting only of data from blood samples
and a model consisting of data from blood samples and physical
examinations were determined.
Evaluating the ability of the model
In the validation of the stroke risk model only the cohorts with
a minimum of 10 years of follow-up were used, excluding 21 797
individuals (24.7%) from the validation (table 1). The validation
of the model was determined by assessing both the predictive
ability and the discrimination of the model.
The predictive ability of the model was determined comparing
observed and predicted events using the HosmereLemeshow
test of goodness of ﬁt and the Brier score. The Spiegelhalter test
was used to test whether adding variables from another step to
the model signiﬁcantly improved the Brier score.
The discriminative ability of the model was assessed using the
area under the receiver operating characteristic curve (AUC). The
AUC was calculated for every model in each of the steps and
tested for signiﬁcant differences using the SAS macro ROC.19
Furthermore, the integrated discrimination improvement (IDI)
and net reclassiﬁcation index (NRI) were calculated.20
In order to prevent the model from being too optimistic and
sensitive to changes in data, the developed stratiﬁed stroke risk
models including competing risk were validated using bootstrap
sampling methods with 1000 repetitions, allowing us to esti-
mate slope shrinkage (a measure of relative calibration) for the
Cox regression models, and the mean of the 1000 Brier scores
and AUC measures, which were compared with the original
estimates.
All analyses were conducted using the statistical software
program SAS version 9.2 (SAS Institute, Cary, North Carolina,
USA) with a statistical signiﬁcance level of 5%, except for the
HosmereLemeshow c2 test where a signiﬁcance level of 1% is
used.
RESULTS
During 1 176 296 person-years of observation 2928 fatal and
non-fatal events of stroke were registered (table 1). The HRs of
the included variables of the risk model are seen in table 2, with
the most important risk factors being diabetes, treatment for
hypertension, smoking and SBP. For women, a positive interac-
tion was seen between country and smoking on the risk of
stroke. The restricted cubic splines are difﬁcult to interpret, but
were used since deviations from linearity were observed.
Graphical presentations showed the expected relationship
between the risk factors and risk of stroke (j-shaped curve
illustrating the relationship between BMI and risk of stroke and
decreasing risk with decreasing HDL cholesteroldﬁgures not
shown).
Predictive ability
The HosmereLemeshow test of goodness of ﬁt showed that the
model was well calibrated in all steps and for all sex- and
country-speciﬁc variations (two-sided p>0.01).
When comparing observed and predicted number of events for
all countries combined we saw that for men the model predicted
extremely well, with a slight tendency towards overestimating
the risk of stroke (table 3). When looking at the countries
individually, we saw a slight overestimation for Denmark,
Sweden, Lithuania and Scotland, whereas for Finland there was
a tendency towards an underestimation.
For women the model with all countries combined had
a tendency to overestimate the risk of stroke (table 4). When
looking at the countries individually, we observed a small over-
estimation in Denmark, a slight underestimation for Finland and
a very large overestimation of stroke risk for Lithuania,
explaining the overestimation of events in the model with
countries combined. For the rest of the countries events were
predicted with great accuracy.
When using the Brier score as a measure of predictive ability
there were generally very low scores, indicating good predictive
ability for all sex- and country-speciﬁc models (tables 3 and 4).
No signiﬁcant differences in Brier scores were observed between
the different steps in the model, neither in total nor within each
country.
Discriminative ability
Discriminative ability measured as the AUC varied between
country- and sex-speciﬁc models.
For men, the model combining all countries showed an
increasing AUC when adding another group of variables to the
Table 2 HRs for the risk of stroke for men and women
HR 95% CI
Men
Diabetes 1.971 1.636 to 2.373
Treatment for hypertension 1.285 1.121 to 1.473
Smoking 1.689 1.528 to 1.868
Systolic BP (mm Hg) 1.016 1.013 to 1.019
Diastolic BP (mm Hg) 1.004 0.999 to 1.010
BMI 0.892 0.843 to 0.945
BMI1* 1.002 1.001 to 1.004
BMI2* 0.994 0.989 to 0.998
Total cholesterol (mmol/l) 1.027 0.985 to 1.072
HDL cholesterol (mmol/l) 0.382 0.221 to 0.662
HDL1y 6.300 0.873 to 45.464
HDL2y 0.017 0.000 to 4.696
Women
Diabetes 2.051 1.661 to 2.511
Treatment for hypertension 1.629 1.410 to 1.878
Smoking3Denmarkz 2.231 1.557 to 3.228
Smoking3Finland 1.615 1.294 to 1.997
Smoking3Sweden 1.171 0.554 to 2.299
Smoking3Poland 6.549 1.881 to 30.023
Smoking3Lithuania 4.841 1.419 to 12.572
Smoking3Russiax e e
Smoking3Italy 1.681 0.859 to 3.007
Smoking3Scotland 2.214 1.766 to 2.779
Systolic BP (mm Hg) 1.011 1.008 to 1.015
Diastolic BP (mm Hg) 1.007 1.001 to 1.014
BMI 0.910 0.853 to 0.978
BMI3BMI{ 1.001 1.000 to 1.003
Total cholesterol (mmol/l) 0.983 0.937 to 1.031
HDL cholesterol (mmol/l) 0.368 0.224 to 0.616
HDL1** 2.284 0.560 to 9.186
HDL2** 0.257 0.003 to 26.124
*BMI as a restricted cubic spline (knots at 5, 35, 65 and 95%).
yHDL cholesterol as a restricted cubic spline (knots at 5, 35, 65 and 95%).
zInteraction between smoking and country.
xNo estimate from Russia since there are no smokers among the stroke cases.
{BMI squared.
**HDL cholesterol as a restricted cubic spline (knots at 5, 35, 65 and 95%).
BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein.
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Table 3 Predictive and discriminative ability of the model for men
Country N Model* Observedy Predictedz Brierx p Value{ AUC** p Valueyy IDIzz p Valuexx
Nordic countries
Denmark 2466 Q 50 60.72 0.0196 0.690
Q+E 50 60.80 0.0195 0.99 0.724 0.01 0.0051 0.05
Q+E+B 50 60.98 0.0195 0.99 0.729 0.16 0.0026 0.19
B 50 60.97 0.0198 0.682
B+E 50 60.77 0.0196 0.98 0.718 0.20 0.0066 0.03
B+E+Q 50 60.98 0.0195 0.98 0.729 0.27 0.0069 0.05
Finland 9217 Q 233 214.51 0.0237 0.812
Q+E 233 211.61 0.0236 0.82 0.824 0.02 0.0057 <0.01
Q+E+B 233 212.50 0.0235 0.99 0.826 0.13 0.0011 0.05
B 233 215.87 0.0239 0.803
B+E 233 212.42 0.0237 0.80 0.821 <0.01 0.0068 <0.01
B+E+Q 233 212.50 0.0235 0.87 0.826 0.12 0.0048 <0.01
Sweden 763 Q 13 16.47 0.0161 0.833
Q+E 13 16.41 0.0162 0.99 0.851 0.41 <0.0001 0.96
Q+E+B 13 16.38 0.0163 0.99 0.845 0.36 0.0039 0.11
B 13 16.31 0.0166 0.745
B+E 13 16.31 0.0166 0.99 0.787 0.28 0.0023 0.42
B+E+Q 13 16.38 0.0163 0.99 0.845 0.03 0.0136 0.08
Eastern European countries
Poland 1066 Q 15 14.22 0.0136 0.685
Q+E 15 14.25 0.0135 0.99 0.766 <0.01 0.0054 <0.01
Q+E+B 15 14.25 0.0135 0.99 0.766 0.99 0.0002 0.35
B 15 14.24 0.0137 0.590
B+E 15 14.29 0.0136 0.99 0.743 <0.01 0.0054 <0.01
B+E+Q 15 14.25 0.0135 0.99 0.766 0.21 0.0019 0.07
Lithuania 1390 Q 28 36.67 0.0198 0.593
Q+E 28 35.31 0.0196 0.99 0.707 0.01 0.0079 0.03
Q+E+B 28 35.34 0.0195 0.99 0.726 0.17 0.0018 0.10
B 28 37.28 0.0198 0.607
B+E 28 35.80 0.0195 0.99 0.718 0.02 0.0095 0.01
B+E+Q 28 35.34 0.0195 0.99 0.726 0.72 <0.0001 0.94
Russia 1483 Q 13 13.44 0.0085 0.817
Q+E 13 13.38 0.0084 0.99 0.859 0.14 0.0078 0.02
Q+E+B 13 13.36 0.0084 0.99 0.856 0.45 0.0002 0.85
B 13 13.50 0.0086 0.803
B+E 13 13.34 0.0085 0.99 0.853 0.01 0.0071 0.02
B+E+Q 13 13.36 0.0084 0.99 0.856 0.82 0.0048 0.14
Middle and Southern European countries
France 7094 Q 84 84.36 0.0116 0.651
Q+E 84 84.25 0.0115 0.99 0.689 0.04 0.0034 <0.01
Q+E+B 84 84.36 0.0115 0.99 0.699 0.12 0.0003 0.18
B 84 84.40 0.0116 0.625
B+E 84 84.39 0.0116 0.99 0.682 0.01 0.0034 <0.01
B+E+Q 84 84.36 0.0115 0.99 0.699 0.22 0.0037 <0.01
Italy 5548 Q 85 84.34 0.0148 0.820
Q+E 85 84.48 0.0146 0.95 0.831 0.11 0.0072 <0.01
Q+E+B 85 84.74 0.0146 0.99 0.831 0.91 <0.0001 0.94
B 85 85.14 0.0148 0.818
B+E 85 85.66 0.0146 0.93 0.835 0.04 0.0091 <0.01
B+E+Q 85 84.74 0.0146 0.98 0.831 0.39 0.0006 0.66
UK
Scotland 7080 Q 161 168.22 0.0218 0.719
Q+E 161 169.33 0.0217 0.91 0.730 0.24 0.0061 <0.01
Q+E+B 161 167.70 0.0217 0.99 0.732 0.51 0.0006 0.21
B 161 166.84 0.0219 0.698
B+E 161 168.29 0.0218 0.94 0.715 0.13 0.0059 <0.01
B+E+Q 161 167.70 0.0217 0.95 0.732 <0.01 0.0031 <0.01
Continued
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model. Adding data from blood samples led to a signiﬁcant yet
minimal increase in discrimination (table 3). The lowest AUC
was seen in the model containing only data from blood samples
(AUC¼0.759) and highest in the model containing all three steps
(AUC¼0.791). When looking at the country-speciﬁc models,
a large AUC close to or above 80% was seen for Finland, Sweden,
Russia and Italy, and all the country-speciﬁc models had
acceptable discriminative ability, with France and Lithuania as
the lowest with an AUC of w70% (table 3). Using IDI, there
was an increasing discrimination with an increasing number of
steps. However, including a third step in a model already
containing data from physical examinations did not result in
signiﬁcant increases in IDI for several countries (table 3), and for
several countries very small increases or even a decrease in IDI
was seen (Sweden, Poland, Lithuania, Russia, France, Italy and
Scotlanddtable 3). Reclassiﬁcation using NRI showed similar
results (table 5A). Adding physical examinations to the model
signiﬁcantly increases classiﬁcation by 8%; however, no
improvements are seen when adding a third step.
For women, a similar picture was seen, although the lack of
increasing discriminative ability when adding data from blood
samples was even clearer using both the IDI and AUC. The
model combining all countries showed an AUC between 0.753
for the model containing data from blood samples alone and
0.801 for the full model (table 4). The same AUC could be
obtained using only data from questionnaires and physical
examinations. When looking at the countries individually, we
see that the models discriminate better for women than for men,
except for Finland and Sweden. The countries where the models
discriminated the best were Poland, Russia and Italy, with an
AUC close to 90% (table 4). When NRI was calculated, only
modest changes were seen in classiﬁcation (table 5B).
The validation using bootstrap sampling methods showed
slope shrinkage close to 1 for all sex- and country-speciﬁc models
(highest 1.0078 and lowest 1.00034), strongly indicating that the
original developed models were robust and not sensitive to
change in data. In the same way, the mean AUC and mean Brier
scores were almost identical to the scores from the original
models.
DISCUSSION
A recent paper from the MORGAM project deals with RR of
stroke in different populations.21 In the present study the
absolute risk of stroke is investigated. It is worth noting that
even the simple model containing only information from either
questions or blood samples had good predictive ability and that
there were no signiﬁcant increases in predictive ability with
increasing steps. However, the discriminative ability of the
model varied between countries and increased when adding
further steps to the model. It is worth noting that the step
including physical examinations seemed to have most inﬂuence
on the discriminative ability, which is not surprising since it
contains BMI and, more importantly, SBP and DBP. When using
the AUC, the combined model for all countries had similar or
even higher discriminative ability than previous models (0.79 for
men and 0.80 for women).4 5 These results show that it is
possible to develop risk estimation models that can be tailored
for different countries and different settings according to data
and resources available. This is of real public health importance
since it is possible to develop simple models with acceptable
performance and use these in low resource healthcare settings.
The strengths of this study lie in the use of data from the
MORGAM collaboration. The use of large cohort studies from
nine countries with a uniform baseline data collection following
the WHO MONICA protocol and the registration of both fatal
and non-fatal stroke cases with strict diagnostic criteria ensures
comparable data for stroke risk estimation. Still some limitations
have to be noted. In this study we do not separate ischaemic and
haemorrhagic strokes since stroke subtype deﬁnition was not
possible in all cases or populations. In some populations, CT
scanners were not available, especially in the ﬁrst years of
registration, or autopsy rates were low in patients dying outside
hospital. Other limitations are the limited number of risk factors
used in the model. Possible risk factors such as alcohol
consumption, physical activity or triglycerides were not avail-
able from all cohorts. The use of diabetes at baseline in the
model results in an exclusion of two Russian cohorts since they
have no information on self-reported diabetes. For the included
cohorts from Russia and Lithuania, 10% and 9%, respectively,
are excluded due to missing data on HDL cholesterol. This may
result in selection bias if the data are not missing at random.
Adding the measure of the competing risk to the developed
model is an important strength of this study. Previous tools for
risk prediction/estimation work under the assumption that
during the period of prediction (eg, 10 years) there are only two
possible disease states. Either you are disease free or you are an
incident case. This is a false assumption since it is possible to die
of a competing event in the same time period. By including the
risk of a competing event, the predictive accuracy of the risk
model will increase. In a recent publication, this approach has
been suggested to be applied to cardiovascular risk estimation.22
The choice of variables included in the model was made
a priori. The model includes diabetes as in several models of risk
Table 3 Continued
Country N Model* Observedy Predictedz Brierx p Value{ AUC** p Valueyy IDIzz p Valuexx
Total
36107 Q 682 692.93 0.0181 0.771
Q+E 682 689.82 0.0180 0.31 0.789 <0.01 0.0057 <0.01
Q+E+B 682 689.62 0.0180 0.97 0.791 0.01 0.0005 0.09
B 682 694.55 0.0182 0.759
B+E 682 691.28 0.0180 0.26 0.782 <0.01 0.0064 <0.01
B+E+Q 682 689.62 0.0180 0.58 0.791 <0.01 0.0036 <0.01
*Q, data from questionnaires, E, data from physical examinations; B, data from blood samples.
yObserved number of events within 10 years.
zPredicted number of events within 10 years.
xBrier score: average discrepancy between observed disease state after 10 years and the estimated risk.
{Comparison of Brier scores between the current and the preceding model.
**Area under the curve.
yyTest of difference between AUC from previous and actual model.
zzIntegrated discrimination improvement. Gained discrimination from previous to present step.
xxTest whether IDI differs from 0.
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Table 4 Predictive and discriminative ability of the model for women
Country N Model* Observedy Predictedz Brierx p Value{ AUC** p Valueyy IDIzz p Valuexx
Nordic countries
Denmark 2512 Q 36 41.29 0.0140 0.779
Q+E 36 41.39 0.0139 0.99 0.801 0.04 0.0039 0.02
Q+E+B 36 41.59 0.0138 0.99 0.804 0.47 0.0039 0.06
B 36 42.91 0.0139 0.739
B+E 36 42.71 0.0138 0.99 0.772 0.01 0.0049 0.01
B+E+Q 36 41.59 0.0138 0.99 0.804 0.02 0.0024 0.33
Finland 10041 Q 158 146.16 0.0152 0.748
Q+E 158 145.78 0.0152 0.99 0.759 0.05 0.0015 0.09
Q+E+B 158 147.10 0.0151 0.99 0.763 0.13 0.0022 <0.01
B 158 148.34 0.0153 0.730
B+E 158 147.58 0.0152 0.97 0.748 0.01 0.0034 <0.01
B+E+Q 158 147.10 0.0151 0.92 0.763 <0.01 0.0057 <0.01
Sweden 762 Q 8 10.00 0.0104 0.704
Q+E 8 9.93 0.0103 0.99 0.778 0.17 0.0044 0.06
Q+E+B 8 9.90 0.0103 0.99 0.779 0.97 0.0026 0.25
B 8 9.91 0.0103 0.666
B+E 8 9.79 0.0102 0.99 0.780 0.19 0.0051 <0.01
B+E+Q 8 9.90 0.0103 0.99 0.779 0.97 0.0022 0.26
Eastern European countries
Poland 1074 Q 7 7.45 0.0063 0.865
Q+E 7 7.39 0.0062 0.99 0.886 0.26 0.0059 0.16
Q+E+B 7 7.38 0.0062 0.99 0.904 0.02 0.0010 0.35
B 7 7.47 0.0063 0.722
B+E 7 7.42 0.0063 0.99 0.838 0.06 0.0048 <0.01
B+E+Q 7 7.38 0.0062 0.99 0.904 0.25 0.0107 0.14
Lithuania 1391 Q 18 36.60 0.0132 0.736
Q+E 18 36.31 0.0131 0.99 0.754 0.35 0.0084 <0.01
Q+E+B 18 36.02 0.0131 0.99 0.746 0.18 0.0001 0.97
B 18 38.84 0.0136 0.681
B+E 18 38.29 0.0134 0.97 0.722 0.05 0.0111 <0.01
B+E+Q 18 36.02 0.0131 0.98 0.746 0.31 0.0117 0.31
Russia 1265 Q 13 13.64 0.0099 0.896
Q+E 13 13.54 0.0098 0.99 0.905 0.20 0.0068 0.12
Q+E+B 13 13.50 0.0097 0.99 0.907 0.63 0.0045 0.32
B 13 13.63 0.0098 0.897
B+E 13 13.54 0.0097 0.99 0.910 0.36 0.0071 0.16
B+E+Q 13 13.50 0.0097 0.99 0.907 0.65 0.0052 0.42
Southern European country
Italy 6038 Q 50 50.87 0.0080 0.856
Q+E 50 50.28 0.0080 0.99 0.878 0.01 0.0037 0.06
Q+E+B 50 50.58 0.0080 0.99 0.882 0.18 0.0012 0.20
B 50 50.56 0.0080 0.844
B+E 50 50.31 0.0080 0.99 0.878 0.02 0.0043 0.05
B+E+Q 50 50.58 0.0080 0.99 0.882 0.57 0.0032 0.19
UK
Scotland 7259 Q 116 115.07 0.0154 0.761
Q+E 116 115.57 0.0154 0.99 0.781 0.03 0.0015 0.46
Q+E+B 116 113.64 0.0154 0.99 0.769 0.02 0.0006 0.40
B 116 113.58 0.0156 0.669
B+E 116 114.10 0.0155 0.98 0.713 <0.01 0.0026 0.14
B+E+Q 116 113.64 0.0154 0.94 0.769 <0.01 0.0058 <0.01
Total
30342 Q 406 421.08 0.0130 0.785
Q+E 406 420.19 0.0129 0.96 0.801 <0.01 0.0026 <0.01
Q+E+B 406 419.71 0.0129 0.94 0.801 0.79 0.0014 <0.01
B 406 425.24 0.0130 0.753
B+E 406 423.73 0.0130 0.77 0.778 <0.01 0.0039 <0.01
B+E+Q 406 419.71 0.0129 0.65 0.801 <0.01 0.0053 <0.01
*Q, data from questionnaires; E, data from physical examinations; B, data from blood samples.
yObserved number of events within 10 years.
zPredicted number of events within 10 years.
xBrier score: average discrepancy between observed disease state after 10 years and the estimated risk.
{Comparison of Brier scores between the current and the preceding model.
**Area under the curve.
yyTest of difference between AUC from previous and actual model.
zzIntegrated discrimination improvement. Gained discrimination from previous to present step.
xxTest whether IDI differs from 0.
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assessment,1 4 6 23 treatment of hypertension as in, for example,
the Framingham Stroke model,24 and the QRISK25 and smoking
as in all risk estimation models. From physical examinations,
BMI, SBP and DBP are obtained. Few models include DBP, but
recent studies from the Framingham Heart Study suggest that
using both SBP and DBP results in models superior to its single
components.26 From blood samples, total and HDL cholesterol
are obtained. The Framingham stroke model1 did not include
lipids, but several models for CVD risk estimation include total
cholesterol2 27 and some include HDL cholesterol.23 27
The purpose of the stepwise approach to risk estimation was
to imitate the clinical setting and to be able to tailor risk esti-
mation models to different settings and still obtain valid esti-
mations of risk. Previously the EUROSTROKE study developed
Table 5 Risk reclassification
(A) Reclassification of risk in men
Risk estimated using only questions Risk estimated using questions and simple examinations
Individuals developing stroke within
10 years of follow-up (n¼682)
<5% 5e10% 10e20% >20% No. up* No. downy
<5% 381 76 2 0
5e10% 46 110 30 1 112 56
10e20% 0 10 22 3
>20% 0 0 0 1
Individuals not developing stroke within 10 years of follow-up (n¼35451)
<5% 31692 774 36 2
5e10% 848 1610 246 6 1071 950
10e20% 1 100 128 7
>20% 0 0 1 0
Net reclassification 0.079; p<0.0001
Risk estimated using questions and
simple examinations
Risk estimated using questions, simple examinations and blood samples
Individuals developing stroke within
10 years of follow-up (n¼682)
<5% 5e10% 10e20% >20% No. up No. down
<5% 411 16 0 0
5e10% 12 174 10 0 26 19
10e20% 0 7 47 0
>20% 0 0 0 5
Individuals not developing stroke within 10 years of follow-up (n¼35451)
<5% 32343 198 0 0
5e10% 203 2233 48 0 250 244
10e20% 0 38 369 4
>20% 0 0 3 12
Net reclassification 0.010; p¼0.3057
(B) Reclassification of risk in women
Risk estimated using only questions Risk estimated using questions and simple examinations
Individuals developing stroke within
10 years of follow-up (n¼406)
<5% 5e10% 10e20% >20% No. up* No. downy
<5% 288 20 0 0
5e10% 23 43 9 1 30 26
10e20% 0 1 19 0
>20% 0 0 2 0
Individuals not developing stroke within 10 years of follow-up (n¼29954)
<5% 28233 306 2 0
5e10% 363 754 79 1 393 431
10e20% 0 61 135 5
>20% 0 0 7 8
Net reclassification 0.011; p¼0.5468
Risk estimated using questions and
simple examinations
Risk estimated using questions, simple examinations and blood samples
Individuals developing stroke within
10 years of follow-up (n¼406)
<5% 5e10% 10e20% >20% No. up No. down
<5% 304 7 0 0
5e10% 6 47 11 0 20 9
10e20% 0 3 25 2
>20% 0 0 0 1
Individuals not developing stroke within 10 years of follow-up (n¼29954)
<5% 28406 190 0 0
5e10% 192 872 57 0 253 242
10e20% 0 46 171 6
>20% 0 0 4 10
Net reclassification 0.027; p¼0.0442
*Individuals moving to higher risk category.
yIndividuals moving to lower risk category.
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a model in three stepsdthat is, patient history, blood pressure
and ﬁbrinogendand concluded that stroke events could be
predicted using only patient history and simple examinations,28
a conclusion which is supported by the ﬁndings from the present
study. Work from the Framingham Heart Study and the
NHANES have assessed the usefulness of a non-laboratory
model substituting serum cholesterol with BMI with good
results,29 30 although the models were developed for CVD and
not for stroke in particular.
A possible limitation of this study is the lack of socioeconomic
status (SES) as a factor in the risk model. Both the ASSIGN and
the QRISK score models have included measures of SES.25 27
Since there is a social gradient in CVD, neglecting SES might
result in a situation where risk of stroke is overestimated in the
higher social groups but underestimated in the lower social
groups.
For the three French PRIME cohorts, the model predicted with
great accuracy but the discrimination was the lowest among the
countries, with an AUC between 0.625 and 0.699. These ﬁndings
persisted when looking at the three French cohorts separately
(data not presented). The most likely explanation is the narrow
age range of the French cohorts at baseline (table 1). The strong
effect of age range of the studied population on the AUC is
a limitation if evaluation of a model is based solely on the AUC.
Diabetes is used self-reported, and the fact that the deﬁnition
of diabetes has changed over time together with the knowledge
that up to 50% of examinees are not aware of their diabetic
status means that the effect of diabetes might be under-reported.
A general limitation of any risk estimation model is that
exposures or risk factor status are only measured once and may
change from baseline and during follow-up. Therefore, some
countries might have experienced a fall in, for example, blood
pressure or smoking, while others have experienced a rise. This
might explain the signiﬁcant interaction between country and
smoking for women seen in table 2.
The present study shows that using a large multicountry
cohort from nine European countries it is possible to develop
a stepwise risk estimation model for 10 year risk of stroke
tailored to different availability of risk factors and still obtain
valid measures of calibration and discrimination even in the
simplest form of the model, with increasing performance of the
model following increasing complexity. The methods chosen
which separate this model from previous models (competing risk
and stepwise approach) should be considered for future risk
estimation models.
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